How should a suspected case of polycythemia vera be managed when JAK2 testing is unavailable?

Managing Suspected Polycythemia Vera Without JAK2 Testing

When JAK2 testing is unavailable, diagnose PV using the revised WHO criteria by demonstrating elevated hemoglobin/hematocrit (≥18.5 g/dL in men, ≥16.5 g/dL in women) plus two of three minor criteria: bone marrow biopsy showing panmyelosis, low serum erythropoietin level, and documented sustained hemoglobin increase >2 g/dL from baseline 1.

Diagnostic Algorithm Without JAK2 Testing

The 2007 WHO revision specifically anticipated this scenario. The diagnostic framework allows PV diagnosis through an alternative pathway when molecular testing is unavailable 1:

Major Criterion (Must Have):

• Hemoglobin ≥18.5 g/dL in men or ≥16.5 g/dL in women
• OR hematocrit ≥55.5% in men or ≥49.5% in women
• OR documented sustained increase in hemoglobin >2 g/dL (20 g/L) from baseline, even if not reaching absolute thresholds 1

Minor Criteria (Need 2 of 3):

1. Bone marrow biopsy: Hypercellularity with trilineage growth (panmyelosis) showing prominent erythroid, granulocytic, and megakaryocytic proliferation 1
2. Serum erythropoietin level: Subnormal or low-normal range 1, 2
3. Endogenous erythroid colony formation (if available)

This alternative combination (first major criterion plus 2 minor criteria) was deliberately designed to capture true PV cases that are JAK2-negative or have mutation burdens too low for detection 1.

Critical Diagnostic Steps

1. Exclude Secondary Causes First

Before pursuing PV diagnosis, systematically rule out 3, 2:

• Hypoxia-related: Chronic lung disease, sleep apnea, high altitude, cyanotic heart disease, smoking
• Renal causes: Renal artery stenosis, renal cell carcinoma, post-renal transplant
• Drug-induced: Testosterone, anabolic steroids, SGLT2 inhibitors, erythropoietin-stimulating agents
• Relative polycythemia: Dehydration, diuretic use, plasma volume contraction

2. Look for Myeloproliferative Features

PV typically presents with additional findings beyond isolated erythrocytosis 4:

• Leukocytosis (>15 × 10⁹/L suggests need for cytoreduction)
• Thrombocytosis (>1500 × 10⁹/L is indication for cytoreduction)
• Splenomegaly (palpable or progressive on imaging)
• Characteristic symptoms: Aquagenic pruritus, erythromelalgia, headache, visual disturbances 3

3. Measure Serum Erythropoietin

A low or low-normal erythropoietin level strongly supports PV diagnosis and serves as a key minor criterion 1, 2, 5. This distinguishes PV from secondary erythrocytosis, where EPO is typically elevated.

4. Obtain Bone Marrow Biopsy

This becomes essential when JAK2 testing is unavailable 1. The characteristic finding is hypercellular marrow with panmyelosis—proliferation across all three lineages (erythroid, granulocytic, megakaryocytic). This histologic pattern is highly specific for PV.

Important Caveats

Iron Deficiency Can Mask PV

Iron deficiency lowers hemoglobin/hematocrit and can create a "masked PV" phenotype 5. Check:

• Ferritin, serum iron, transferrin saturation
• Mean corpuscular volume (MCV <83 fL suggests iron restriction)

The guidelines acknowledge that in routine practice, you should not be prevented from making a working diagnosis of PV in the presence of iron deficiency, even if WHO hemoglobin thresholds aren't met 1. However, for formal diagnosis (research/trials), demonstrate criteria fulfillment after iron replacement.

Historical Hematocrit Trends Matter

Review longitudinal hematocrit/hemoglobin values 2. A documented sustained increase >2 g/dL from baseline can substitute for absolute threshold values as the first major criterion 1.

Management Without JAK2 Confirmation

Once you've established a working diagnosis using clinical criteria:

All Patients (Regardless of Risk):

• Phlebotomy to maintain hematocrit <45% (strong recommendation) 6
  • Induction: 300-450 mL weekly or twice weekly until target reached
  • Maintenance: Same volume, frequency determined by hematocrit monitoring
• Low-dose aspirin daily (unless contraindicated) 6, 4
• Aggressive cardiovascular risk factor management 6

High-Risk Patients (Age >60 OR Prior Thrombosis):

• Add cytoreductive therapy 6
• First-line options: Hydroxyurea OR interferon-alpha 6
• Use caution with hydroxyurea in young patients; prefer interferon-alpha for long-term treatment in younger individuals 6

Additional Indications for Cytoreduction:

• Poor phlebotomy tolerance 6
• Symptomatic/progressive splenomegaly 6
• Severe disease-related symptoms 6
• Platelets >1500 × 10⁹/L 6
• Leukocytes >15 × 10⁹/L 6

Pitfalls to Avoid

1. Don't wait for JAK2 results to treat thrombotic risk: The revised criteria were designed to allow diagnosis and treatment initiation without molecular confirmation 1

2. Don't use cytoreductive therapy in low-risk patients: Phlebotomy and aspirin are sufficient 6

3. Don't ignore the bone marrow biopsy: When JAK2 is unavailable, this becomes your most important diagnostic tool 1

4. Don't overlook iron deficiency: It can completely obscure the diagnosis, creating normal or near-normal hemoglobin levels despite underlying PV 5

The strength of this approach lies in the 2007 WHO expert panel's foresight in creating diagnostic pathways that don't absolutely require molecular testing 1, combined with the 2018 European LeukemiaNet's clear management algorithms based on thrombotic risk stratification 6.